International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease

Journal of Clinical Oncology

Volumn 31, Issue 18, 2013, Pages 2347-2357

  Terpos, Evangelos ^a   Morgan, Gareth ^b   Dimopoulos, Meletios A ^a   Drake, Matthew T ^c   Lentzsch, Suzanne ^d   Raje, Noopur ^e   Sezer, Orhan ^f   García Sanz, Ramón ^g   Shimizu, Kazuyuki ^h   Turesson, Ingemar ⁱ   Reiman, Tony ^j   Jurczyszyn, Artur ^k   Merlini, Giampaolo ^l   Spencer, Andrew ⁿ   Leleu, Xavier ^o   Cavo, Michele ^m   Munshi, Nikhil ^e   Rajkumar, S Vincent ^c   Durie, Brian G M ^p   Roodman, G David ^q  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c MAYO CLINIC   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY OF SALAMANCA   (Spain)

^h Nagoya City Midori General Hospital   (Japan)

ⁱ MALMÖ UNIVERSITY   (Sweden)

^j UNIVERSITY OF NEW BRUNSWICK   (Canada)

^k UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^l UNIVERSITY OF PAVIA   (Italy)

^m UNIVERSITY OF BOLOGNA   (Italy)

ⁿ MONASH UNIVERSITY   (Australia)

^o LILLE UNIVERSITY HOSPITAL   (France)

^p Samuel Oschin Comprehensive Cancer Center Institute   (United States)

^q INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADVERSE OUTCOME; ARTICLE; BONE DISEASE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPRESSION FRACTURE; CONSULTATION; DRUG ADMINISTRATION ROUTE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; JAW OSTEONECROSIS; KYPHOPLASTY; LONG BONE; LOW ENERGY RADIATION; META ANALYSIS (TOPIC); MULTIPLE MYELOMA; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PATHOLOGIC FRACTURE; PERCUTANEOUS VERTEBROPLASTY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINAL CORD COMPRESSION; SPINE INSTABILITY; TREATMENT DURATION; BONE NECROSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG COMBINATION; FRACTURE; INTERNATIONAL COOPERATION; INTRAVENOUS ADMINISTRATION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY;

ADMINISTRATION, INTRAVENOUS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; CLODRONIC ACID; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FRACTURES, BONE; HUMANS; IMIDAZOLES; INTERNATIONAL COOPERATION; MAGNETIC RESONANCE IMAGING; MEDICAL ONCOLOGY; MULTIPLE MYELOMA; OSTEONECROSIS; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84883021288     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.7901     Document Type: Article

References (90)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. Parker SL, Davis KJ, Wingo PA, et al: Cancer statistics by race and ethnicity. CA Cancer J Clin 48:31-48, 1998
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520, 2008
4. Kastritis E, Zervas K, Symeonidis A, et al: Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). Leukemia 23:1152-1157, 2009
5. Kyle RA, Gertz MA, Witzig TE, et al: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21-33, 2003
6. Terpos E, Dimopoulos MA: Myeloma bone disease: Pathophysiology and management. Ann Oncol 16:1223-1231, 2005
7. Raje N, Roodman GD: Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 17:1278-1286, 2011
8. Coleman RE: Skeletal complications of malignancy. Cancer 80:1588-1594, 1997
9. Roodman GD: Novel targets for myeloma bone disease. Expert Opin Ther Targets 12:1377-1387, 2008
10. Croucher PI, Apperley JF: Bone disease in multiple myeloma. Br J Haematol 103:902-910, 1998
11. Cocks K, Cohen D, Wisløff F, et al: An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQMY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43:1670-1678, 2007
12. Bruce NJ, McCloskey EV, Kanis JA, et al: Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol 104:358-364, 1999
13. McCloskey EV, MacLennan IC, Drayson MT, et al: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma: MRC Working Party on Leukaemia in Adults. Br J Haematol 100:317-325, 1998
14. Anderson KC, Alsina M, Bensinger W, et al: Multiple myeloma: Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 5:118-147, 2007
15. Kyle RA, Yee GC, Somerfield MR, et al: American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25:2464-2472, 2007
16. Lacy MQ, Dispenzieri A, Gertz MA, et al: Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81:1047-1053, 2006
17. Harousseau JL, Greil R, Kloke O: ESMO minimum clinical recommendations for diagnosis, treatment, and follow-up of multiple myeloma. Ann Oncol 16:i45-i47, 2005 (suppl 1)
18. Durie BG: Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc 82:516-517, 2007
19. Terpos E, Sezer O, Croucher PI, et al: The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20:1303-1317, 2009
20. Terpos E, Dimopoulos MA, Sezer O, et al: The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group. Leukemia 24:1700-1712, 2010
21. Kyle RA, Durie BG, Rajkumar SV, et al: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121-1127, 2010
22. Hussein MA, Vrionis FD, Allison R, et al: The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group consensus statement. Leukemia 22:1479-1484, 2008
23. Lahtinen R, Laakso M, Palva I, et al: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma: Finnish Leukaemia Group. Lancet 340:1049-1052, 1992
24. Laakso M, Lahtinen R, Virkkunen P, et al: Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma: Finnish Leukaemia Group. Br J Haematol 87:725-729, 1994
25. McCloskey EV, Dunn JA, Kanis JA, et al: Long-Term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113:1035-1043, 2001
26. Brincker H, Westin J, Abildgaard N, et al: Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial-Danish-Swedish Co-operative Study Group. Br J Haematol 101:280-286, 1998
27. Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group. N Engl J Med 334:488-493, 1996
28. Berenson JR, Lichtenstein A, Porter L, et al: Long-Term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events: Myeloma Aredia Study Group. J Clin Oncol 16:593-602, 1998
29. Menssen HD, Sakalová A, Fontana A, et al: Effects of long-Term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20:2353-2359, 2002
30. Gimsing P, Carlson K, Turesson I, et al: Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): A doubleblind, randomised controlled trial. Lancet Oncol 11: 973-982, 2010
31. Berenson JR, Rosen LS, Howell A, et al: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91: 1191-1200, 2001
32. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001
33. Rosen LS, Gordon D, Kaminski M, et al: Long-Term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744, 2003
34. Morgan GJ, Davies FE, Gregory WM, et al: First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial. Lancet 376:1989-1999, 2010
35. Morgan GJ, Child JA, Gregory WM, et al: Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): Secondary outcomes from a randomised controlled trial. Lancet Oncol 12:743-752, 2011
36. Morgan GJ, Davies FE, Gregory WM, et al: Effects of induction and maintenance plus long-Term bisphosphonates on bone disease in patients with multiple myeloma: MRC Myeloma IX trial. Blood 119:5374-5383, 2012
37. Mhaskar R, Redzepovic J, Wheatley K, et al: Bisphosphonates in multiple myeloma: A network meta-Analysis. Cochrane Database Syst Rev 5:CD003188, 2012
38. D'Arena G, Gobbi PG, Broglia C, et al: Pamidronate versus observation in asymptomatic myeloma: Final results with long-Term follow-up of a randomized study. Leuk Lymphoma 52:771-775, 2011
39. Musto P, Petrucci MT, Bringhen S, et al: A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 113:1588-1595, 2008
40. Moulopoulos LA, Dimopoulos MA, Smith TL, et al: Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 13:251-256, 1995
41. Hillengass J, Fechtner K, Weber MA, et al: Prognostic significance of focal lesions in wholebody magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28: 1606-1610, 2010
42. Bida JP, Kyle RA, Therneau TM, et al: Disease associations with monoclonal gammopathy of undetermined significance: A population-based study of 17, 398 patients. Mayo Clin Proc 84:685-693, 2009
43. Kristinsson SY, Tang M, Pfeiffer RM, et al: Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: A populationbased study. Blood 116:2651-2655, 2010
44. Berenson JR, Yellin O, Boccia RV, et al: Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin Cancer Res 14:6289-6295, 2008
45. Pepe J, Petrucci MT, Mascia ML, et al: The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance. Calcif Tissue Int 82:418-426, 2008
46. Fechtner K, Hillengass J, Delorme S, et al: Staging monoclonal plasma cell disease: Comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. Radiology 257:195-204, 2010
47. Cramer JA, Gold DT, Silverman SL, et al: A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031, 2007
48. Mangiapane S, Hoer A, Gothe H, et al: Higher persistency with i.v. bisphosphonates in patients with bone metastasis. J Clin Oncol 24:698s, 2006 (suppl; abstr 18623)
49. Chern B, Joseph D, Joshua D, et al: Bisphosphonate infusions: Patient preference, safety and clinic use. Support Care Cancer 12:463-466, 2004
50. Attal M, Harousseau JL, Leyvraz S, et al: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289-3294, 2006
51. Roux S, Bergot C, Fermand JP, et al: Evaluation of bone mineral density and fat-lean distribution in patients with multiple myeloma in sustained remission. J Bone Miner Res 18:231-236, 2003
52. Corso A, Varettoni M, Zappasodi P, et al: A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:1545-1548, 2007
53. Peter R, Mishra V, Fraser WD: Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ 328:335-336, 2004
54. Badros A, Goloubeva O, Terpos E, et al: Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol 142: 492-494, 2008
55. Laroche M, Lemaire O, Attal M: Vitamin D deficiency does not alter biochemical markers of bone metabolism before or after autograft in patients with multiple myeloma. Eur J Haematol 85: 65-67, 2010
56. Ross AC, Manson JE, Abrams SA, et al: The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 96:53-58, 2011
57. Munier A, Gras V, Andrejak M, et al: Zoledronic acid and renal toxicity: Data from French adverse effect reporting database. Ann Pharmacother 39:1194-1197, 2005
58. Banerjee D, Asif A, Striker L, et al: Short-Term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 41:E18, 2003
59. Henry DH, Costa L, Goldwasser F, et al: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-1132, 2011
60. Markowitz GS, Fine PL, D'Agati V D: Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 39:1118-1122, 2002
61. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al: Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 91:968-971, 2006
62. Zervas K, Verrou E, Teleioudis Z, et al: Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 134:620-623, 2006
63. Badros A, Terpos E, Katodritou E, et al: Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 26:5904-5909, 2008
64. Dimopoulos MA, Kastritis E, Bamia C, et al: Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117-120, 2009
65. Ripamonti CI, Maniezzo M, Campa T, et al: Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates: The experience of the National Cancer Institute of Milan. Ann Oncol 20:137-145, 2009
66. Montefusco V, Gay F, Spina F, et al: Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 49:2156-2162, 2008
67. Berenson J, Pflugmacher R, Jarzem P, et al: Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: A multicentre, randomised controlled trial. Lancet Oncol 12:225-3596, 2011
68. Bouza C, Ló pez-Cuadrado T, Cediel P, et al: Balloon kyphoplasty in malignant spinal fractures: A systematic review and meta-Analysis. BMC Palliat Care 8:12, 2009
69. Lieberman I, Reinhardt MK: Vertebroplasty and kyphoplasty for osteolytic vertebral collapse. Clin Orthop Relat Res 415:S176-S186, 2003
70. Kö se KC, Cebesoy O, Akan B, et al: Functional results of vertebral augmentation techniques in pathological vertebral fractures of myelomatous patients. J Natl Med Assoc 98:1654-1658, 2006
71. Pflugmacher R, Schulz A, Schroeder RJ, et al: A prospective two-year follow-up of thoracic and lumbar osteolytic vertebral fractures caused by multiple myeloma treated with balloon kyphoplasty [in German]. Z Orthop Ihre Grenzgeb 145:39-47, 2007
72. Pflugmacher R, Taylor R, Agarwal A, et al: Balloon kyphoplasty in the treatment of metastatic disease of the spine: A 2-year prospective evaluation. Eur Spine J 17:1042-1048, 2008
73. Lane JM, Hong R, Koob J, et al: Kyphoplasty enhances function and structural alignment in multiple myeloma. Clin Orthop Relat Res 49-53, 2004
74. Fourney DR, Schomer DF, Nader R, et al: Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 98:21-30, 2003 (suppl)
75. McDonald RJ, Trout AT, Gray LA, et al: Vertebroplasty in multiple myeloma: Outcomes in a large patient series. AJNR Am J Neuroradiol 29:642-648, 2008
76. Huber F, McArthur N, Tanner M, et al: Kyphoplasty for patients with multiple myeloma is a safe surgical procedure: Results from a large patient cohort. Clin Lymphoma Myeloma 9:375-380, 2009
77. Zou J, Mei X, Gan M, et al: Kyphoplasty for spinal fractures from multiple myeloma. J Surg Oncol 102:43-47, 2010
78. Dalbayrak S, Onen M, Yilmaz M, et al: Clinical and radiographic results of balloon kyphoplasty for treatment of vertebral body metastases and multiple myelomas. J Clin Neurosci 17:219-224, 2010
79. Chew C, Craig L, Edwards R, et al: Safety and efficacy of percutaneous vertebroplasty in malignancy: A systematic review. Clin Radiol 66:63-72, 2011
80. Buchbinder R, Osborne RH, Ebeling PR, et al: A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med 361: 557-568, 2009
81. Kallmes DF, Comstock BA, Heagerty PJ, et al: A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med 361:569-579, 2009
82. Bhargava A, Trivedi D, Kalva L, et al: Management of cancer-related vertebral compression fracture: Comparison of treatment options-A literature meta-Analysis. J Clin Oncol 27, 2009 (suppl; abstr e20529)
83. Rades D, Hoskin PJ, Stalpers LJ, et al: Shortcourse radiotherapy is not optimal for spinal cord compression due to myeloma. Int J Radiat Oncol Biol Phys 64:1452-1457, 2006
84. Hirsch AE, Jha RM, Yoo AJ, et al: The use of vertebral augmentation and external beam radiation therapy in the multimodal management of malignant vertebral compression fractures. Pain Physician 14: 447-458, 2011
85. Balducci M, Chiesa S, Manfrida S, et al: Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: Long-Term experience. Strahlenther Onkol 187:114-119, 2011
86. Price P, Hoskin PJ, Easton D, et al: Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 6:247-255, 1986
87. Mak KS, Lee LK, Mak RH, et al: Incidence and treatment patterns in hospitalizations for malignant spinal cord compression in the United States, 1998-2006. Int J Radiat Oncol Biol Phys 80:824-831, 2011
88. Rades D, Veninga T, Stalpers LJ, et al: Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases. J Clin Oncol 25:50-56, 2007
89. Wedin R: Surgical treatment for pathologic fracture. Acta Orthop Scand Suppl 72:1-29, 2001
90. Utzschneider S, Schmidt H, Weber P, et al: Surgical therapy of skeletal complications in multiple myeloma. Int Orthop 35:1209-1213, 2011